Cymbalta Could Get "Fairly Narrow Broad Indication" For Pain, FDA's Rappaport Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency favors a claim for musculoskeletal pain, but advisory committee members suggest considering the cause, not just the location of the pain, in the indication.